Substances and Drug Testing Panels

A drug test detects only the substances and analytes included in its ordered panel. A “drug test” is therefore not one universal examination. The panel, specimen, initial method, confirmatory method, and cutoff concentrations all determine what a result can show.

This hub explains common drug categories and panel terminology. Return to Drug Testing: The Complete Guide for the full testing process.

What is a drug-testing panel?

A panel is the list of drugs, drug classes, metabolites, or markers that a test is designed to evaluate. A panel may be fixed by a regulator, selected by a clinician, customized by an employer, ordered by a court, or built into an at-home device.

The number in a panel’s name is only a shorthand. A five-panel test generally refers to five drug categories, but the specific analytes can vary. A ten-panel product from one laboratory may not match a ten-panel product from another. Opioid coverage is especially important: a basic “opiates” assay may not include fentanyl, buprenorphine, methadone, or every semisynthetic opioid.

Common substance categories

Cannabis and THC metabolites

Many urine programs test for a metabolite associated with THC rather than THC itself. Oral-fluid and blood tests may target different analytes. A result indicates that the targeted analyte met the program’s criteria; it does not by itself show the exact time, dose, source, frequency, or level of impairment.

Hemp-derived and CBD products create additional questions because labeling and THC content may vary. Federal workplace rules and state employment protections must be considered separately. Read the Cannabis and THC Drug Testing guide.

Opioids, opiates, and fentanyl

“Opiates” and “opioids” are not interchangeable panel specifications. An assay designed around morphine-like compounds may not adequately detect every prescription or synthetic opioid. Fentanyl usually requires a specific assay. The requisition or product label should identify the substances and metabolites included.

A confirmed result may also require medical review because some opioids are lawfully prescribed. Read the Opioid and Fentanyl Drug Testing guide.

Amphetamines, methamphetamine, and cocaine

Stimulant panels can include amphetamine, methamphetamine, MDMA-related analytes, and the principal cocaine metabolite. Initial immunoassay screens may recognize a drug class, while confirmation identifies specific analytes. Certain results require careful review of prescriptions, over-the-counter products, and laboratory differentiation.

Read the Stimulant Drug Testing guide.

Prescription medications

Benzodiazepines, barbiturates, methadone, oxycodone, and other medications may be included in expanded panels. A test cannot determine from concentration alone whether a medication was taken exactly as directed. Clinical interpretation may require the medication list, dose timing, metabolism, specimen type, and definitive analysis.

Read Prescription Medications and Drug Testing.

Five-, ten-, and twelve-panel tests

Five-panel tests

A traditional five-panel framework commonly includes amphetamines, cocaine, cannabis, an opiate/opioid category, and PCP. However, authorized analytes can change, and the category may include multiple specific drugs. Federal agency panels follow the current HHS authorized testing panel rather than a generic retail definition.

Ten-panel tests

A ten-panel test often adds categories such as benzodiazepines, barbiturates, methadone, or other drugs to a basic panel. There is no single universal ten-panel configuration. The actual list must be verified.

Twelve-panel and expanded tests

Expanded tests may add oxycodone, buprenorphine, fentanyl, tramadol, synthetic cannabinoids, ketamine, gabapentin, or other substances. Whether expansion is appropriate depends on the testing purpose, prevalence, clinical relevance, legal authority, and the availability of validated confirmation.

See Five-, Ten-, and Twelve-Panel Drug Tests Explained.

Questions to ask about any panel

  • Which drugs and metabolites are included by name?
  • Which specimen is used?
  • What are the initial and confirmatory methods?
  • What cutoffs apply at each stage?
  • Does the panel include fentanyl and commonly prescribed opioids?
  • What happens after a presumptive positive?
  • Is an MRO or other qualified reviewer involved?
  • Which laws, regulations, contracts, or clinical policies govern the test?

Panel results and impairment

A panel result should be interpreted within its intended purpose. Detecting a metabolite may establish prior exposure but not current impairment. A negative result means only that the reported analytes did not meet the applicable criteria in that specimen. It does not rule out every drug, every time period, or every pattern of use.

Continue with Drug-Test Cutoff Levels and Understanding Drug-Test Results.

Sources

Last evidence review: October 29, 2026.